Rexahn Pharmaceuticals?has entered into a clinical trial collaboration agreement with?Merck?to evaluate the combination of Rexahn’s RX-5902 and Merck’s anti-PD-1 therapy, KEYTRUDA? (pembrolizumab) in a Phase 2 trial in patients with metastatic triple nega